CA
NZ
UK
AU
IND
US
…
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
PTC Therapeutics is a biopharmaceutical company focused on therapies for rare genetic disorders, employing small molecules, RNA-directed approaches and gene-modifying technologies. Long-term growth may be supported by regulatory approvals and commercialization of late-stage candidates, expansion into additional indications and partnerships.
Principal risks are clinical and regulatory setbacks, small patient populations with reimbursement uncertainty, and high R&D and commercial costs that may force additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 696.62M | -363.12M | -696.11M | -587.49M | -518.34M |
| Net income | 682.64M | -363.30M | -626.60M | -559.02M | -523.90M |
| Selling general administrative | 347.14M | 300.91M | 348.97M | 300.10M | 285.27M |
| Gross profit | 1658.90M | 749.38M | 872.34M | 654.12M | 506.26M |
| Reconciled depreciation | 38.81M | 75.66M | 194.75M | 128.84M | 64.13M |
| Ebit | 848.85M | -196.13M | -566.93M | -439.93M | -374.94M |
| Ebitda | 887.66M | -120.46M | -330.34M | -372.58M | -378.07M |
| Depreciation and amortization | 38.81M | 75.66M | 236.59M | 67.35M | -3.12M |
| Non operating income net other | - | - | - | -49.21M | -57.88M |
| Operating income | 856.51M | -302.57M | -439.50M | -439.93M | -374.94M |
| Other operating expenses | 874.15M | 1109.35M | 1377.32M | 1138.73M | 913.54M |
| Interest expense | 152.23M | 166.99M | 129.18M | 90.87M | 86.02M |
| Tax provision | 13.97M | 0.18M | -87.05M | -28.47M | 5.56M |
| Net interest income | -152.23M | -166.99M | -109.41M | -90.87M | -86.02M |
| Non recurring | - | - | - | 33.38M | - |
| Income tax expense | 13.97M | 0.18M | -69.51M | -28.47M | 5.56M |
| Total revenue | 1730.65M | 806.78M | 937.82M | 698.80M | 538.59M |
| Total operating expenses | 802.39M | 1051.95M | 1311.84M | 1094.05M | 881.21M |
| Cost of revenue | 71.75M | 57.40M | 65.49M | 44.68M | 32.33M |
| Total other income expense net | -159.89M | -60.55M | -256.61M | -147.56M | -143.40M |
| Net income from continuing ops | 682.64M | -363.30M | -641.70M | -559.02M | -523.90M |
| Net income applicable to common shares | - | - | - | -559.02M | -523.90M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2898.77M | 1705.02M | 1903.18M | 1705.62M | 1938.06M |
| Intangible assets | 388.75M | 118.79M | 379.50M | 705.89M | 724.84M |
| Other current assets | 67.31M | 44.09M | 150.29M | 105.66M | -126.31M |
| Total liab | 3104.08M | 2803.09M | 2721.74M | 2052.70M | 1936.62M |
| Total stockholder equity | -205.31M | -1098.07M | -818.55M | -347.09M | 1.44M |
| Deferred long term liab | - | - | - | 102.83M | 137.11M |
| Other current liab | 335.79M | 282.32M | 580.25M | 365.25M | 60.75M |
| Common stock | 0.08M | 0.08M | 0.07M | 0.07M | 0.07M |
| Capital stock | 0.08M | 0.08M | 0.07M | 0.07M | 0.07M |
| Retained earnings | -2964.23M | -3646.87M | -3283.58M | -2656.97M | -2097.96M |
| Other liab | - | - | - | 269.48M | 1051.70M |
| Good will | 82.34M | 82.34M | 82.34M | 82.34M | 82.34M |
| Other assets | - | - | - | 33.38M | 46.50M |
| Cash | 984.65M | 779.71M | 594.00M | 410.70M | 773.38M |
| Total current liabilities | 968.43M | 580.98M | 603.10M | 406.24M | 509.35M |
| Current deferred revenue | 2.04M | 5.50M | 0.80M | 1.35M | 265.75M |
| Net debt | 1722.42M | 1691.36M | -178.97M | 292.92M | -341.94M |
| Short term debt | 585.12M | 271.18M | 16.00M | 12.37M | 159.81M |
| Short long term debt | 569.63M | 257.82M | 194.31M | - | 149.54M |
| Short long term debt total | 2707.06M | 2471.07M | 415.03M | 703.63M | 431.43M |
| Other stockholder equity | 2748.34M | 2574.61M | 2466.23M | 2305.02M | 2123.61M |
| Property plant equipment | - | - | - | 72.59M | 130.01M |
| Total current assets | 2273.95M | 1365.53M | 1218.63M | 693.78M | 773.38M |
| Net tangible assets | - | - | - | -1135.32M | -805.74M |
| Short term investments | 960.72M | 359.99M | 282.74M | 130.87M | 583.66M |
| Net receivables | 181.62M | 158.55M | 161.02M | 155.61M | 110.45M |
| Long term debt | 2025.37M | 2109.37M | 1904.00M | 571.72M | 281.89M |
| Inventory | 79.65M | 23.19M | 30.58M | 21.81M | 15.86M |
| Accounts payable | 45.49M | 17.27M | 6.04M | 27.27M | 23.03M |
| Accumulated other comprehensive income | 10.50M | -25.89M | -1.28M | 4.80M | -24.28M |
| Common stock total equity | - | - | - | 0.07M | 0.07M |
| Retained earnings total equity | - | - | - | -2656.97M | -2097.96M |
| Non currrent assets other | 18.30M | 20.70M | 19.96M | 48.58M | 227.49M |
| Non current assets total | 624.82M | 339.49M | 684.55M | 1011.83M | 1164.68M |
| Capital lease obligations | 112.07M | 103.88M | 130.81M | 131.91M | 103.94M |
| Long term debt total | - | - | - | 571.72M | 281.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -562.04M | 44.18M | -49.88M | 442.64M | 304.51M |
| Change to liabilities | - | - | - | 22.98M | 41.65M |
| Total cashflows from investing activities | -861.98M | 44.18M | -176.74M | 290.18M | 219.18M |
| Net borrowings | -1.61M | -1.49M | -301.38M | 138.55M | -2.22M |
| Total cash from financing activities | 331.09M | 255.87M | 646.40M | 167.95M | 20.88M |
| Change to operating activities | - | - | - | -68.69M | -22.25M |
| Net income | 682.64M | -363.30M | -626.60M | -559.02M | -523.90M |
| Change in cash | 203.02M | 185.03M | 314.36M | 98.71M | -19.09M |
| Begin period cash flow | 795.32M | 610.28M | 295.93M | 197.22M | 216.31M |
| End period cash flow | 998.33M | 795.32M | 610.28M | 295.93M | 197.22M |
| Total cash from operating activities | 711.20M | -107.69M | -158.42M | -356.65M | -251.33M |
| Issuance of capital stock | - | 0.00M | 0.00M | 50.00M | 0.00M |
| Depreciation | 38.81M | 75.66M | 236.59M | 128.84M | 64.13M |
| Other cashflows from investing activities | -291.08M | 110.31M | -92.18M | -120.44M | -57.12M |
| Change to inventory | -53.90M | 6.16M | -8.18M | -6.67M | 1.80M |
| Change to account receivables | -10.15M | 1.73M | -1.54M | -48.47M | -44.99M |
| Sale purchase of stock | - | - | - | 71.08M | 23.10M |
| Other cashflows from financing activities | 233.66M | 257.36M | 947.78M | 269.23M | 23.10M |
| Change to netincome | - | - | - | 113.77M | 230.38M |
| Capital expenditures | 300.01M | 74.25M | 120.62M | 152.46M | 85.33M |
| Change receivables | - | - | - | -48.47M | -44.99M |
| Cash flows other operating | - | - | - | -11.71M | 54.74M |
| Cash and cash equivalents changes | - | - | - | 101.48M | -11.27M |
| Change in working capital | -47.88M | 102.54M | -4.00M | -85.33M | -23.79M |
| Stock based compensation | 74.55M | 74.61M | 131.21M | 110.33M | 103.51M |
| Other non cash items | -36.93M | 58.70M | 151.32M | 82.81M | 128.33M |
| Free cash flow | 411.18M | -181.94M | -279.04M | -509.11M | -336.66M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics Inc |
-4.49 6.97% |
59.97 | - | 24.27 | 5.43 | 1743.27 | 3.98 | 23.14 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
500 Warren Corporate Center Drive, Warren, NJ, United States, 07059
908 222 7000
991
| Name | Title | Year Born |
|---|---|---|
| Dr. Stuart W. Peltz Ph.D. | Co-Founder, CEO & Exec. Director | 1960 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 1946 |
| Ms. Emily Luisa Hill | Chief Financial Officer | 1980 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 1967 |
| Mr. Mark Elliott Boulding | Exec. VP & Chief Legal Officer | 1961 |
| Mr. Eric Pauwels | Chief Bus. Officer | 1961 |
| Ms. Dawn A. Svoronos | Advisor | 1953 |
| Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS | Chief Operating Officer | 1972 |
| Ms. Christine Utter | Sr. VP, Chief Accounting Officer & Head of People Services | 1978 |
| Ms. Ellen Welch Ph.D. | Chief Scientific Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...